Format

Send to

Choose Destination
Nature. 2013 Sep 19;501(7467):355-64. doi: 10.1038/nature12627.

Tumour heterogeneity in the clinic.

Author information

1
Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, Ontario, Canada.

Abstract

Recent therapeutic advances in oncology have been driven by the identification of tumour genotype variations between patients, called interpatient heterogeneity, that predict the response of patients to targeted treatments. Subpopulations of cancer cells with unique genomes in the same patient may exist across different geographical regions of a tumour or evolve over time, called intratumour heterogeneity. Sequencing technologies can be used to characterize intratumour heterogeneity at diagnosis, monitor clonal dynamics during treatment and identify the emergence of clinical resistance during disease progression. Genetic interpatient and intratumour heterogeneity can pose challenges for the design of clinical trials that use these data.

PMID:
24048068
PMCID:
PMC5224525
DOI:
10.1038/nature12627
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center